MEF2D and B-cell acute lymphoblastic leukemia: MEF2D has been reported to serve as oncogene in B cell acute lymphoblastic leukemia [15] and hepatocellular carcinoma [16, 32–34] through promotion of colony formation and proliferation, inhibition of apoptosis, epithelial-mesenchymal transition and invasiveness.